Is it possible to improve neurodevelopmental abnormalities in Down syndrome?

Reviews in the Neurosciences

Volumn 22, Issue 4, 2011, Pages 419-455

  Bartesaghi, Renata ^a   Guide, Sandra ^a   Ciani, Elisabetta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

brain hypotrophy; cognitive disability; dendritic pathology; neurogenesis impairment; pharmacotherapy; synaptic alterations

Indexed keywords

BRAIN DEVELOPMENT; DEVELOPMENTAL DISORDER; DOWN SYNDROME; HUMAN; INTELLECTUAL IMPAIRMENT; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRISOMY 21;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 21; DEVELOPMENTAL DISABILITIES; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HUMANS; MICE; NERVE DEGENERATION;

EID: 80051768234     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/RNS.2011.037     Document Type: Review

References (331)

1. Abraham, H., Tornoczky, T., Kosztolanyi, G., and Seress, L. (2001). Cell formation in the cortical layers of the developing human cerebellum. Int. J. Dev. Neurosci. 19, 53-62. (Pubitemid 32156974)
2. Ahn, K.J., Jeong, H.K., Choi, H.S., Ryoo, S.R., Kim, Y.J., Goo, J.S., Choi, S.Y., Han, J.S., Ha, I., and Song, W.J. (2006). DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis. 22, 463-472. (Pubitemid 43832120)
3. Ait Yahya-Graison, E., Aubert, J., Dauphinot, L., Rivals, I., Prieur, M., Golfier, G., Rossier, J., Personnaz, L., Creau, N., Blehaut, H., et al. (2007). Classification of human chromosome 21 geneexpression variations in Down syndrome: Impact on disease phenotypes. Am. J. Hum. Genet. 81, 475-491. (Pubitemid 47330207)
4. Aldridge, K., Reeves, R.H., Olson, L.E., and Richtsmeier, J.T. (2007). Differential effects of trisomy on brain shape and volume in related aneuploid mouse models. Am. J. Med. Genet. A 143A, 1060-1070. (Pubitemid 46709276)
5. Altafaj, X., Dierssen, M., Baamonde, C., Marti, E., Visa, J., Guimera, J., Oset, M., Gonzalez, J.R., Florez, J., Fillat, C., et al. (2001). Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 10, 1915-1923. (Pubitemid 32910536)
6. Altafaj, X., Ortiz-Abalia, J., Fernandez, M., Potier, M.C., Laffaire, J., Andreu, N., Dierssen, M., Gonzalez-Garcia, C., Cena, V., Marti, E., et al. (2008). Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiol. Dis. 32, 377-384.
7. Altman, J. and Bayer, S.A. (1990). Migration and distribution of two populations of hippocampal granule cell precursors during the perinatal and postnatal periods. J. Comp. Neurol. 301, 365-381. (Pubitemid 20368500)
8. Alves da Costa, C., Sunyach, C., Pardossi-Piquard, R., Sevalle, J., Vincent, B., Boyer, N., Kawarai, T., Girardot, N., St George- Hyslop, P., and Checler, F. (2006). Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J. Neurosci. 26, 6377-6385.
9. Amano, K., Sago, H., Uchikawa, C., Suzuki, T., Kotliarova, S.E., Nukina, N., Epstein, C.J., and Yamakawa, K. (2004). Dosagedependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. Hum. Mol. Genet. 13, 1333-1340. (Pubitemid 38967186)
10. Antonarakis, S.E., Lyle, R., Dermitzakis, E.T., Reymond, A., and Deutsch, S. (2004). Chromosome 21 and down syndrome: From genomics to pathophysiology. Nat. Rev. Genet. 5, 725-738. (Pubitemid 39336357)
11. Arai, Y., Ijuin, T., Takenawa, T., Becker, L.E., and Takashima, S. (2002). Excessive expression of synaptojanin in brains with Down syndrome. Brain Dev. 24, 67-72. (Pubitemid 34224905)
12. Azkona, G., Amador-Arjona, A., Obradors-Tarrago, C., Varea, E., Arque, G., Pinacho, R., Fillat, C., de la Luna, S., Estivill, X., and Dierssen, M. (2010a). Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2. Genes Brain Behav. 9, 160-172.
13. Azkona, G., Levannon, D., Groner, Y., and Dierssen, M. (2010b). In vivo effects of APP are not exacerbated by BACE2 co-overexpression: Behavioural characterization of a double transgenic mouse model. Amino Acids 39, 1571-1580.
14. Baek, K.H., Zaslavsky, A., Lynch, R.C., Britt, C., Okada, Y., Siarey, R.J., Lensch, M.W., Park, I.H., Yoon, S.S., Minami, T., et al. (2009). Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459, 1126-1130.
15. Baffico, M., Perroni, L., Rasore-Quartino, A., and Scartezzini, P. (1989). Expression of the human ETS-2 oncogene in normal fetal tissues and in the brain of a fetus with trisomy 21. Hum. Genet. 83, 295-296. (Pubitemid 19250493)
16. Bahn, S., Mimmack, M., Ryan, M., Caldwell, M.A., Jauniaux, E., Starkey, M., Svendsen, C.N., and Emson, P. (2002). Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: A gene expression study. Lancet 359, 310-315. (Pubitemid 34119295)
17. Bain, J., McLauchlan, H., Elliott, M., and Cohen, P. (2003). The specificities of protein kinase inhibitors: An update. Biochem. J. 371, 199-204. (Pubitemid 36458094)
18. Bairy, K.L., Madhyastha, S., Ashok, K.P., Bairy, I., and Malini, S. (2007). Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 79, 1-11. (Pubitemid 46034171)
19. Banik, N.L., Davison, A.N., Palo, J., and Savolainen, H. (1975). Biochemical studies on myelin isolated from the brains of patients with Down's syndrome. Brain 98, 213-218.
20. Bar-Peled, O., Gross-Isseroff, R., Ben-Hur, H., Hoskins, I., Groner, Y., and Biegon, A. (1991). Fetal human brain exhibits a prenatal peak in the density of serotonin 5-HT1A receptors. Neurosci. Lett. 127, 173-176.
21. Bar-Peled, O., Korkotian, E., Segal, M., and Groner, Y. (1996). Constitutive overexpression of Cu/Zn superoxide dismutase exacerbates kainic acid-induced apoptosis of transgenic-Cu/Zn superoxide dismutase neurons. Proc. Natl. Acad. Sci. USA 93, 8530-8535. (Pubitemid 26269593)
22. Baxter, L.L., Moran, T.H., Richtsmeier, J.T., Troncoso, J., and Reeves, R.H. (2000). Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum. Mol. Genet. 9, 195-202. (Pubitemid 30052743)
23. Becker, L.E., Armstrong, D.L., and Chan, F. (1986). Dendritic atrophy in children with Down's syndrome. Ann. Neurol. 20, 520-526. (Pubitemid 16005672)
24. Becker, L., Mito, T., Takashima, S., and Onodera, K. (1991). Growth and development of the brain in Down syndrome. Prog. Clin. Biol. Res. 373, 133-152.
25. Belichenko, P.V., Masliah, E., Kleschevnikov, A.M., Villar, A.J., Epstein, C.J., Salehi, A., and Mobley, W.C. (2004). Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J. Comp. Neurol. 480, 281-298. (Pubitemid 39578025)
26. Belichenko, P.V., Kleschevnikov, A.M., Salehi, A., Epstein, C.J., and Mobley, W.C. (2007). Synaptic and cognitive abnormalities in mouse models of Down syndrome: Exploring genotype-phenotype relationships. J. Comp. Neurol. 504, 329-345. (Pubitemid 47437199)
27. Belichenko, N.P., Belichenko, P.V., Kleschevnikov, A.M., Salehi, A., Reeves, R.H., and Mobley, W.C. (2009a). The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J. Neurosci. 29, 5938-5948.
28. Belichenko, P.V., Kleschevnikov, A.M., Masliah, E., Wu, C., Takimoto-Kimura, R., Salehi, A., and Mobley, W.C. (2009b). Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 512, 453-466.
29. Belichenko, P.V., Wright, E.E., Belichenko, N.P., Masliah, E., Li, H.H., Mobley, W.C., and Francke, U. (2009c). Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: Evidence for disruption of neuronal networks. J. Comp. Neurol. 514, 240-258.
30. Bell, K., Shokrian, D., Potenzieri, C., and Whitaker-Azmitia, P.M. (2003). Harm avoidance, anxiety, and response to novelty in the adolescent S-100beta transgenic mouse: Role of serotonin and relevance to Down syndrome. Neuropsychopharmacology 28, 1810-1816. (Pubitemid 41070846)
31. Benavides-Piccione, R., Ballesteros-Yanez, I., de Lagran, M.M., Elston, G., Estivill, X., Fillat, C., Defelipe, J., and Dierssen, M. (2004). On dendrites in Down syndrome and DS murine models: A spiny way to learn. Prog. Neurobiol. 74, 111-126. (Pubitemid 39423861)
32. Berger-Sweeney, J. and Hohmann, C.F. (1997). Behavioral consequences of abnormal cortical development: Insights into developmental disabilities. Behav. Brain Res. 86, 121-142. (Pubitemid 27154256)
33. Best, T.K., Siarey, R.J., and Galdzicki, Z. (2007). Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. J. Neurophysiol. 97, 892-900. (Pubitemid 46143403)
34. Bhattacharyya, A., McMillan, E., Chen, S.I., Wallace, K., and Svendsen, C.N. (2009). A critical period in cortical interneuron neurogenesis in down syndrome revealed by human neural progenitor cells. Dev. Neurosci. 31, 497-510.
35. Bianchi, P., Ciani, E., Contestabile, A., Guidi, S., and Bartesaghi, R. (2010a). Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol. 20, 106-118.
36. Bianchi, P., Ciani, E., Guidi, S., Trazzi, S., Felice, D., Grossi, G., Fernandez, M., Giuliani, A., Calza, L., and Bartesaghi, R. (2010b). Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 30, 8769-8779.
37. Bimonte-Nelson, H.A., Hunter, C.L., Nelson, M.E., and Granholm, A.C. (2003). Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav. Brain Res. 139, 47-57. (Pubitemid 36300789)
38. Blum, D., Chtarto, A., Tenenbaum, L., Brotchi, J., and Levivier, M. (2004). Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 17, 359-366. (Pubitemid 39574870)
39. Boylan, K., Romero, S., and Birmaher, B. (2007). Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacology (Berl) 191, 27-38. (Pubitemid 46294941)
40. Brazel, C.Y., Romanko, M.J., Rothstein, R.P., and Levison, S.W. (2003). Roles of the mammalian subventricular zone in brain development. Prog. Neurobiol. 69, 49-69. (Pubitemid 36293991)
41. Busciglio, J., and Yankner, B.A. (1995). Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378, 776-779. (Pubitemid 26004408)
42. Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H., and Yankner, B.A. (2002). Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33, 677-688. (Pubitemid 34219240)
43. Busciglio, J., Pelsman, A., Helguera, P., Ashur-Fabian, O., Pinhasov, A., Brenneman, D.E., and Gozes, I. (2007). NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr. Pharm. Des. 13, 1091-1098. (Pubitemid 46739338)
44. Bustin, M., Alfonso, P.J., Pash, J.M., Ward, J.M., Gearhart, J.D., and Reeves, R.H. (1995). Characterization of transgenic mice with an increased content of chromosomal protein HMG-14 in their chromatin. DNA Cell Biol. 14, 997-1005. (Pubitemid 26002056)
45. Campenot, R.B. and MacInnis, B.L. (2004). Retrograde transport of neurotrophins: Fact and function. J. Neurobiol. 58, 217-229. (Pubitemid 38173720)
46. Cao, X. and Sudhof, T.C. (2001). A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293, 115-120. (Pubitemid 32625507)
47. Capone, G. (2006). Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 142, 158-172. (Pubitemid 44298198)
48. Carlesimo, G.A., Marotta, L., and Vicari, S. (1997). Long-term memory in mental retardation: Evidence for a specific impairment in subjects with Down's syndrome. Neuropsychologia 35, 71-79. (Pubitemid 26418235)
49. Carr, J. and Hollins, S. (1995). Menopause in women with learning disabilities. J Intellect. Disabil. Res. 39 (Pt 2), 137-139.
50. Cataldo, A.M., Petanceska, S., Peterhoff, C.M., Terio, N.B., Epstein, C.J., Villar, A., Carlson, E.J., Staufenbiel, M., and Nixon, R.A. (2003). App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J. Neurosci. 23, 6788-6792. (Pubitemid 36951206)
51. Chakrabarti, L., Galdzicki, Z., and Haydar, T.F. (2007). Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J. Neurosci. 27, 11483-11495. (Pubitemid 350006912)
52. Chakrabarti, L., Best, T.K., Cramer, N.P., Carney, R.S., Isaac, J.T., Galdzicki, Z., and Haydar, T.F. (2010). Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat. Neurosci. 13, 927-934.
53. Chang, Q. and Gold, P.E. (2008). Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome. Neurobiol. Learn. Mem. 89, 167-177. (Pubitemid 350235961)
54. Chang, K.T., Shi, Y.J., and Min, K.T. (2003). The Drosophila homolog of Down's syndrome critical region 1 gene regulates learning: Implications for mental retardation. Proc. Natl. Acad. Sci. USA 100, 15794-15799. (Pubitemid 38021069)
55. Chao, M.V. and Hempstead, B.L. (1995). p75 and Trk: A tworeceptor system. Trends Neurosci. 18, 321-326.
56. Chao, M., Casaccia-Bonnefil, P., Carter, B., Chittka, A., Kong, H., and Yoon, S.O. (1998). Neurotrophin receptors: Mediators of life and death. Brain Res. Brain Res. Rev. 26, 295-301. (Pubitemid 28318084)
57. Chao, M.V., Rajagopal, R., and Lee, F.S. (2006). Neurotrophin signalling in health and disease. Clin. Sci. (Lond) 110, 167-173. (Pubitemid 43241478)
58. Chapman, R.S. and Hesketh, L.J. (2000). Behavioral phenotype of individuals with Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 6, 84-95. (Pubitemid 30399531)
59. Chen, J.K., Taipale, J., Young, K.E., Maiti, T., and Beachy, P.A. (2002). Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA 99, 14071-14076. (Pubitemid 35257626)
60. Chen-Hwang, M.C., Chen, H.R., Elzinga, M., and Hwang, Y.W. (2002). Dynamin is a minibrain kinase/dual specificity Yak1- related kinase 1A substrate. J. Biol. Chem. 277, 17597-17604. (Pubitemid 34967562)
61. Cheon, M.S., Fountoulakis, M., Dierssen, M., Ferreres, J.C., and Lubec, G. (2001). Expression profiles of proteins in fetal brain with Down syndrome. J. Neural. Transm. Suppl. 61, 311-319. (Pubitemid 38085093)
62. Chopra, I. and Roberts, M. (2001). Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232-260. (Pubitemid 32538179)
63. Chrast, R., Scott, H.S., Madani, R., Huber, L., Wolfer, D.P., Prinz, M., Aguzzi, A., Lipp, H.P., and Antonarakis, S.E. (2000). Mice trisomic for a bacterial artificial chromosome with the singleminded 2 gene (Sim2) show phenotypes similar to some of those present in the partial trisomy 16 mouse models of Down syndrome. Hum. Mol. Genet. 9, 1853-1864. (Pubitemid 30608618)
64. Chu, K.O., Wang, C.C., Chu, C.Y., Choy, K.W., Pang, C.P., and Rogers, M.S. (2007). Uptake and distribution of catechins in fetal organs following in utero exposure in rats. Hum. Reprod. 22, 280-287. (Pubitemid 44942698)
65. Clark, S., Schwalbe, J., Stasko, M.R., Yarowsky, P.J., and Costa, A.C. (2006). Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp. Neurol. 200, 256-261. (Pubitemid 44080763)
66. Contestabile, A., Fila, T., Bartesaghi, R., Contestabile, A., Ciani, E. (2006). Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. J. Neurochem. 97, 515-526.
67. Contestabile, A., Fila, T., Ceccarelli, C., Bonasoni, P., Bonapace, L., Santini, D., Bartesaghi, R., and Ciani, E. (2007). Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 17, 665-678. (Pubitemid 47292037)
68. Contestabile, A., Fila, T., Bartesaghi, R., and Ciani, E. (2009). Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn mouse, an animal model for Down syndrome. Brain Pathol. 19, 224-237.
69. Cooper, J.D., Salehi, A., Delcroix, J.D., Howe, C.L., Belichenko, P.V., Chua-Couzens, J., Kilbridge, J.F., Carlson, E.J., Epstein, C.J., and Mobley, W.C. (2001). Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. USA 98, 10439-10444. (Pubitemid 32803038)
70. Coppus, A.M., Evenhuis, H.M., Verberne, G.J., Visser, F.E., Eikelenboom, P., van Gool, W.A., Janssens, A.C., and van Duijn, C.M. (2010). Early age at menopause is associated with increased risk of dementia and mortality in women with Down syndrome. J. Alzheimers Dis. 19, 545-550.
71. Cortez, M.A., Shen, L., Wu, Y., Aleem, I.S., Trepanier, C.H., Sadeghnia, H.R., Ashraf, A., Kanawaty, A., Liu, C.C., Stewart, L., et al. (2009). Infantile spasms and Down syndrome: A new animal model. Pediatr. Res. 65, 499-503.
72. Costa, A.C., Walsh, K., and Davisson, M.T. (1999). Motor dysfunction in a mouse model for Down syndrome. Physiol. Behav. 68, 211-220. (Pubitemid 30009803)
73. Coyle, J.T., Oster-Granite, M.L., and Gearhart, J.D. (1986). The neurobiologic consequences of Down syndrome. Brain Res. Bull. 16, 773-787. (Pubitemid 16041613)
74. Crapper-McLachlan, D.R. (1986). Clinical expression of Alzheimer's disease in Down's syndrome. Psychiatr. Clin. North Am. 9, 659-670. (Pubitemid 17195080)
75. da Nobrega, A.M., Nunesmaia, H.G., Viana Nde, O., and Filgueiras, M.A. (1999). Electroencephalographic modification in Down syndrome. Arq. Neuropsiquiatr. 57, 580-586.
76. Dauphinot, L., Lyle, R., Rivals, I., Dang, M.T., Moldrich, R.X., Golfier, G., Ettwiller, L., Toyama, K., Rossier, J., Personnaz, L., et al. (2005). The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Hum. Mol. Genet. 14, 373-384. (Pubitemid 40220654)
77. Davisson, M.T., Schmidt, C., Reeves, R.H., Irving, N.G., Akeson, E.C., Harris, B.S., and Bronson, R.T. (1993). Segmental trisomy as a mouse model for Down syndrome. Prog. Clin. Biol. Res. 384, 117-133.
78. de la Monte, S.M., Sohn, Y.K., Ganju, N., and Wands, J.R. (1998). P53-and CD95-associated apoptosis in neurodegenerative diseases. Lab. Invest. 78, 401-411. (Pubitemid 28207853)
79. Delabar, J.M., Theophile, D., Rahmani, Z., Chettouh, Z., Blouin, J.L., Prieur, M., Noel, B., and Sinet, P.M. (1993). Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur. J. Hum. Genet. 1, 114-124.
80. Delcroix, J.D., Valletta, J., Wu, C., Howe, C.L., Lai, C.F., Cooper, J.D., Belichenko, P.V., Salehi, A., and Mobley, W.C. (2004). Trafficking the NGF signal: Implications for normal and degenerating neurons. Prog. Brain Res. 146, 3-23. (Pubitemid 37541372)
81. Demas, G.E., Nelson, R.J., Krueger, B.K., and Yarowsky, P.J. (1996). Spatial memory deficits in segmental trisomic Ts65Dn mice. Behav. Brain Res. 82, 85-92. (Pubitemid 27033629)
82. Devinsky, O., Sato, S., Conwit, R.A., and Schapiro, M.B. (1990). Relation of EEG alpha background to cognitive function, brain atrophy, and cerebral metabolism in Down's syndrome. Agespecific changes. Arch. Neurol. 47, 58-62. (Pubitemid 20024156)
83. Dierssen, M., Vallina, I.F., Baamonde, C., Garcia-Calatayud, S., Lumbreras, M.A., and Florez, J. (1997). Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. Brain Res. 749, 238-244. (Pubitemid 27104205)
84. Dierssen, M., Fillat, C., Crnic, L., Arbones, M., Florez, J., and Estivill, X. (2001). Murine models for Down syndrome. Physiol. Behav. 73, 859-871. (Pubitemid 32885574)
85. Dierssen, M., Benavides-Piccione, R., Martinez-Cue, C., Estivill, X., Florez, J., Elston, G.N., and DeFelipe, J. (2003). Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: Effects of environmental enrichment. Cereb. Cortex 13, 758-764. (Pubitemid 36758962)
86. Doetsch, F., Garcia Verdugo, J.M., and Alvarez Buylla, A. (1997). Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J. Neurosci. 17, 5046-5061. (Pubitemid 27263818)
87. Dong, H., Yuede, C.M., Coughlan, C., Lewis, B., and Csernansky, J.G. (2008). Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease. Neuropsychopharmacology 33, 3226-3236.
88. Dorsey, S.G., Renn, C.L., Carim-Todd, L., Barrick, C.A., Bambrick, L., Krueger, B.K., Ward, C.W., and Tessarollo, L. (2006). In vivo restoration of physiological levels of truncated TrkB.T1 receptor rescues neuronal cell death in a trisomic mouse model. Neuron 51, 21-28. (Pubitemid 43963340)
89. Downes, E.C., Robson, J., Grailly, E., Abdel-All, Z., Xuereb, J., Brayne, C., Holland, A., Honer, W.G., and Mukaetova-Ladinska, E.B. (2008). Loss of synaptophysin and synaptosomalassociated protein 25-kDa (SNAP-25) in elderly Down syndrome individuals. Neuropathol. Appl. Neurobiol. 34, 12-22.
90. Dykens, E., Hodapp, R., and Evans, D. (1994). Profiles and development of adaptive behavior in children with Down syndrome. Am. J. Ment. Retard. 98, 580-587. (Pubitemid 24096754)
91. Einarson, A., Choi, J., Einarson, T.R., and Koren, G. (2009). Incidence of major malformations in infants following antidepressant exposure in pregnancy: Results of a large prospective cohort study. Can. J. Psychiatry 54, 242-246.
92. Ellis, J.M., Tan, H.K., Gilbert, R.E., Muller, D.P., Henley, W., Moy, R., Pumphrey, R., Ani, C., Davies, S., Edwards, V., et al. (2008). Supplementation with antioxidants and folinic acid for children with Down's syndrome: Randomised controlled trial. BMJ 336, 594-597. (Pubitemid 351439516)
93. Elson, A., Levanon, D., Weiss, Y., and Groner, Y. (1994). Overexpression of liver-type phosphofructokinase (PFKL) in transgenic-PFKL mice: Implication for gene dosage in trisomy 21. Biochem. J. 299 (Pt 2), 409-415. (Pubitemid 24114133)
94. Encinas, J.M., Vaahtokari, A., and Enikolopov, G. (2006). Fluoxetine targets early progenitor cells in the adult brain. Proc. Natl. Acad. Sci. USA 103, 8233-8238. (Pubitemid 43801081)
95. Engidawork, E., Gulesserian, T., Fountoulakis, M., and Lubec, G. (2003). Aberrant protein expression in cerebral cortex of fetus with Down syndrome. Neuroscience 122, 145-154. (Pubitemid 37329954)
96. Escorihuela, R.M., Vallina, I.F., Martinez-Cue, C., Baamonde, C., Dierssen, M., Tobena, A., Florez, J., and Fernandez-Teruel, A. (1998). Impaired short-and long-term memory in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 247, 171-174. (Pubitemid 28240124)
97. Fernandez, F. and Garner, C.C. (2008). Episodic-like memory in Ts65Dn, a mouse model of Down syndrome. Behav. Brain Res. 188, 233-237. (Pubitemid 351178776)
98. Fernandez, F., Morishita, W., Zuniga, E., Nguyen, J., Blank, M., Malenka, R.C., and Garner, C.C. (2007). Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411-413. (Pubitemid 46494581)
99. Fernandez, F., Trinidad, J.C., Blank, M., Feng, D.D., Burlingame, A.L., and Garner, C.C. (2009). Normal protein composition of synapses in Ts65Dn mice: A mouse model of Down syndrome. J. Neurochem. 110, 157-169.
100. Fernandez-Martinez, J., Vela, E.M., Tora-Ponsioen, M., Ocana, O.H., Nieto, M.A., and Galceran, J. (2009). Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A. J. Cell. Sci. 122, 1574-1583.
101. Fernandez-Teruel, A., Escorihuela, R.M., Castellano, B., Gonzalez, B., and Tobena, A. (1997). Neonatal handling and environmental enrichment effects on emotionality, novelty/reward seeking, and age-related cognitive and hippocampal impairments: Focus on the Roman rat lines. Behav. Genet. 27, 513-526. (Pubitemid 28098959)
102. Ferrer, I. and Gullotta, F. (1990). Down's syndrome and Alzheimer's disease: Dendritic spine counts in the hippocampus. Acta Neuropathol. 79, 680-685. (Pubitemid 20170346)
103. Fiedler, J.L., Epstein, C.J., Rapoport, S.I., Caviedes, R., and Caviedes, P. (1994). Regional alteration of cholinergic function in central neurons of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome). Brain Res. 658, 27-32. (Pubitemid 24291699)
104. Fischer, D.F., van Dijk, R., Sluijs, J.A., Nair, S.M., Racchi, M., Levelt, C.N., van Leeuwen, F.W., and Hol, E.M. (2005). Activation of the Notch pathway in Down syndrome: Cross-talk of Notch and APP. FASEB J. 19, 1451-1458. (Pubitemid 41279003)
105. Fleisher, A.S., Raman, R., Siemers, E.R., Becerra, L., Clark, C.M., Dean, R.A., Farlow, M.R., Galvin, J.E., Peskind, E.R., Quinn, J.F., et al. (2008). Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031-1038.
106. Frank-Kamenetsky, M., Zhang, X.M., Bottega, S., Guicherit, O., Wichterle, H., Dudek, H., Bumcrot, D., Wang, F.Y., Jones, S., Shulok, J., et al. (2002). Small-molecule modulators of Hedgehog signaling: Identification and characterization of Smoothened agonists and antagonists. J. Biol. 1, 10.
107. Fuentes, J.J., Pritchard, M.A., Planas, A.M., Bosch, A., Ferrer, I., and Estivill, X. (1995). A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum. Mol. Genet. 4, 1935-1944.
108. Fuentes, J.J., Genesca, L., Kingsbury, T.J., Cunningham, K.W., Perez-Riba, M., Estivill, X., and de la Luna, S. (2000). DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurinmediated signaling pathways. Hum. Mol. Genet. 9, 1681-1690. (Pubitemid 30427005)
109. Fukuda, Y., Berry, T.L., Nelson, M., Hunter, C.L., Fukuhara, K., Imai, H., Ito, S., Granholm-Bentley, A.C., Kaplan, A.P., and Mutoh, T. (2010). Stimulated neuronal expression of brain-derived neurotrophic factor by Neurotropin. Mol. Cell. Neurosci. 45, 226-233.
110. Gahtan, E., Auerbach, J.M., Groner, Y., and Segal, M. (1998). Reversible impairment of long-term potentiation in transgenic Cu/Zn-SOD mice. Eur. J. Neurosci. 10, 538-544. (Pubitemid 28325477)
111. Galante, M., Jani, H., Vanes, L., Daniel, H., Fisher, E.M., Tybulewicz, V.L., Bliss, T.V., and Morice, E. (2009). Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Hum. Mol. Genet. 18, 1449-1463.
112. Galdzicki, Z. and Siarey, R.J. (2003). Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav. 2, 167-178. (Pubitemid 36898803)
113. Gandolfi, A., Horoupian, D.S., and De Teresa, R.M. (1981). Pathology of the auditory system in autosomal trisomies with morphometric and quantitative study of the ventral cochlear nucleus. J. Neurol. Sci. 51, 43-50. (Pubitemid 11078502)
114. Garcez, M.E., Peres, W., and Salvador, M. (2005). Oxidative stress and hematologic and biochemical parameters in individuals with Down syndrome. Mayo Clin. P. 80, 1607-1611. (Pubitemid 41747063)
115. Geling, A., Steiner, H., Willem, M., Bally-Cuif, L., and Haass, C. (2002). A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep. 3, 688-694.
116. Gerlai, R. and Roder, J. (1995). Abnormal exploratory behavior in transgenic mice carrying multiple copies of the human gene for S100 beta. J. Psychiatry Neurosci. 20, 105-112.
117. Ghosal, K., Stathopoulos, A., and Pimplikar, S.W. (2010). APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One 5, e11866.
118. Godridge, H., Reynolds, G.P., Czudek, C., Calcutt, N.A., and Benton, M. (1987). Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J. Neurol. Neurosurg. Psychiatry 50, 775-778. (Pubitemid 17076293)
119. Golden, J.A. and Hyman, B.T. (1994). Development of the superior temporal neocortex is anomalous in trisomy 21. J. Neuropathol. Exp. Neurol. 53, 513-520. (Pubitemid 24276810)
120. Gozes, I., Morimoto, B.H., Tiong, J., Fox, A., Sutherland, K., Dangoor, D., Holser-Cochav, M., Vered, K., Newton, P., Aisen, P.S., et al. (2005). NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 11, 353-368.
121. Gozes, I., Divinski, I., and Piltzer, I. (2008). NAP and D-SAL: Neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci. 9 (Suppl. 3), S3.
122. Granholm, A.C., Sanders, L.A., and Crnic, L.S. (2000). Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp. Neurol. 161, 647-663. (Pubitemid 30137022)
123. Granholm, A.C., Ford, K.A., Hyde, L.A., Bimonte, H.A., Hunter, C.L., Nelson, M., Albeck, D., Sanders, L.A., Mufson, E.J., and Crnic, L.S. (2002). Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol. Behav. 77, 371-385. (Pubitemid 35373893)
124. Granholm, A.C., Sanders, L., Seo, H., Lin, L., Ford, K., and Isacson, O. (2003). Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome. Hippocampus 13, 905-914. (Pubitemid 38100740)
125. Greenough, W.T., Volkmar, F.R., and Juraska, J.M. (1973). Effects of rearing complexity on dendritic branching in frontolateral and temporal cortex of the rat. Exp. Neurol. 41, 371-378.
126. Greenough, W.T., Larson, J.R., and Withers, G.S. (1985). Effects of unilateral and bilateral training in a reaching task on dendritic branching of neurons in the rat motor-sensory forelimb cortex. Behav. Neural Biol. 44, 301-314. (Pubitemid 16193388)
127. Griffin, W.S., Stanley, L.C., Ling, C., White, L., MacLeod, V., Perrot, L.J., White, C.L., 3rd and Araoz, C. (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86, 7611-7615. (Pubitemid 19254506)
128. Griffin, W.S., Sheng, J.G., McKenzie, J.E., Royston, M.C., Gentleman, S.M., Brumback, R.A., Cork, L.C., Del Bigio, M.R., Roberts, G.W., and Mrak, R.E. (1998). Life-long overexpression of S100beta in Down's syndrome: Implications for Alzheimer pathogenesis. Neurobiol. Aging 19, 401-405. (Pubitemid 29065489)
129. Gropp, A., Kolbus, U., and Giers, D. (1975). Systematic approach to the study of trisomy in the mouse. II. Cytogenet. Cell Genet. 14, 42-62.
130. Guedj, F., Sebrie, C., Rivals, I., Ledru, A., Paly, E., Bizot, J.C., Smith, D., Rubin, E., Gillet, B., Arbones, M., et al. (2009). Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 4, e4606.
131. Guidi, S., Bonasoni, P., Ceccarelli, C., Santini, D., Gualtieri, F., Ciani, E., and Bartesaghi, R. (2008). Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol. 18, 180-197. (Pubitemid 351430398)
132. Guidi, S., Ciani, E., Bonasoni, P., Santini, D., and Bartesaghi, R. (2011a). Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. Brain Pathol. 21, 361-373.
133. Guidi, S., Stagni, F., Ragazzi, E., Bianchi, P., Ciani, E., and Bartesaghi, R. (2011b). Pharmacotherapy with fluoxetine rescues dendritic hypotrophy in the Ts65Dn mouse model for DS. 8th World Congress of IBRO, Florence, Italy, July 14-18, 2011.
134. Guimera, J., Casas, C., Estivill, X., and Pritchard, M. (1999). Human minibrain homologue (MNBH/DYRK1): Characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics 57, 407-418. (Pubitemid 29239228)
135. Gulesserian, T., Engidawork, E., Fountoulakis, M., and Lubec, G. (2001). Antioxidant proteins in fetal brain: Superoxide dismutase- 1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J. Neural. Transm. Suppl. 61, 71-84. (Pubitemid 38085073)
136. Gulesserian, T., Kim, S.H., Fountoulakis, M., and Lubec, G. (2002). Aberrant expression of centractin and capping proteins, integral constituents of the dynactin complex, in fetal down syndrome brain. Biochem. Biophys. Res. Commun. 291, 62-67. (Pubitemid 34681138)
137. Hammerle, B., Carnicero, A., Elizalde, C., Ceron, J., Martinez, S., and
138. Hampton, T.G., Stasko, M.R., Kale, A., Amende, I., and Costa, A.C. (2004). Gait dynamics in trisomic mice: Quantitative neurological traits of Down syndrome. Physiol. Behav. 82, 381-389. (Pubitemid 38981625)
139. Harashima, C., Jacobowitz, D.M., Witta, J., Borke, R.C., Best, T.K., Siarey, R.J., and Galdzicki, Z. (2006). Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: A model of Down syndrome. J. Comp. Neurol. 494, 815-833. (Pubitemid 43054228)
140. Harris-Cerruti, C., Kamsler, A., Kaplan, B., Lamb, B., Segal, M., and Groner, Y. (2004). Functional and morphological alterations in compound transgenic mice overexpressing Cu/Zn superoxide dismutase and amyloid precursor protein [correction]. Eur. J. Neurosci. 19, 1174-1190. (Pubitemid 38387195)
141. Hata, T., Kita, T., Itoh, E., Oyama, R., and Kawabata, A. (1988). Mechanism of the analgesic effect of neurotropin. Jpn. J. Pharmacol. 48, 165-173.
142. Haydar, T.F., Blue, M.E., Molliver, M.E., Krueger, B.K., and Yarowsky, P.J. (1996). Consequences of trisomy 16 for mouse brain development: Corticogenesis in a model of Down syndrome. J. Neurosci. 16, 6175-6182. (Pubitemid 26313992)
143. Haydar, T.F., Nowakowski, R.S., Yarowsky, P.J., and Krueger, B.K. (2000). Role of founder cell deficit and delayed neuronogenesis in microencephaly of the trisomy 16 mouse. J. Neurosci. 20, 4156-4164. (Pubitemid 30365686)
144. Helguera, P., Pelsman, A., Pigino, G., Wolvetang, E., Head, E., and Busciglio, J. (2005). ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J. Neurosci. 25, 2295-2303. (Pubitemid 40322270)
145. Hewitt, C.A., Ling, K.H., Merson, T.D., Simpson, K.M., Ritchie, M.E., King, S.L., Pritchard, M.A., Smyth, G.K., Thomas, T., Scott, H.S., et al. (2010). Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome. PLoS One 5, e11561.
146. Holtzman, D.M., Santucci, D., Kilbridge, J., Chua-Couzens, J., Fontana, D.J., Daniels, S.E., Johnson, R.M., Chen, K., Sun, Y., Carlson, E., et al. (1996). Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. USA 93, 13333-13338. (Pubitemid 26382816)
147. Hunter, C.L., Bachman, D., and Granholm, A.C. (2004). Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann. Neurol. 56, 675-688. (Pubitemid 39540748)
148. Ikonomov, O.C. and Manji, H.K. (1999). Molecular mechanisms underlying mood stabilization in manic-depressive illness: The phenotype challenge. Am. J. Psychiatry 156, 1506-1514. (Pubitemid 29459980)
149. Incerti, M., Toso, L., Vink, J., Roberson, R., Nold, C., Abebe, D., and Spong, C.Y. (2011). Prevention of learning deficit in a Down syndrome model. Obstet. Gynecol. 117, 354-361.
150. Inestrosa, N.C., Marzolo, M.P., and Bonnefont, A.B. (1998). Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease. Mol. Neurobiol. 17, 73-86. (Pubitemid 29030732)
151. Insausti, A.M., Megias, M., Crespo, D., Cruz-Orive, L.M., Dierssen, M., Vallina, I.F., Insausti, R., and Florez, J. (1998). Hippocampal volume and neuronal number in Ts65Dn mice: A murine model of Down syndrome. Neurosci. Lett. 253, 175-178. (Pubitemid 28442591)
152. Isbrucker, R.A., Bausch, J., Edwards, J.A., and Wolz, E. (2006). Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: Genotoxicity. Food Chem. Toxicol. 44, 626-635.
153. Ishihara, K., Amano, K., Takaki, E., Ebrahim, A.S., Shimohata, A., Shibazaki, N., Inoue, I., Takaki, M., Ueda, Y., Sago, H., et al. (2009). Increased lipid peroxidation in Down's syndrome mouse models. J. Neurochem. 110, 1965-1976.
154. Ishihara, K., Amano, K., Takaki, E., Shimohata, A., Sago, H., Epstein, C.J., and Yamakawa, K. (2010). Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb. Cortex 20, 1131-1143.
155. Janssen, I.M., Sturtz, S., Skipka, G., Zentner, A., Garrido, M.V., and Busse, R. (2010). Ginkgo biloba in Alzheimer's disease: A systematic review. Wien Med. Wochenschr. 160, 539-546.
156. Jhoo, J.H., Kim, H.C., Nabeshima, T., Yamada, K., Shin, E.J., Jhoo, W.K., Kim, W., Kang, K.S., Jo, S.A., and Woo, J.I. (2004). Beta-amyloid (1-42)-induced learning and memory deficits in mice: Involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav. Brain Res. 155, 185-196. (Pubitemid 39208900)
157. Jovanovic, S.V., Clements, D., and MacLeod, K. (1998). Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic. Biol. Med. 25, 1044-1048. (Pubitemid 28558330)
158. Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.P., and van den Bussche, H. (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ 331, 321-327.
159. Kahlem, P., Sultan, M., Herwig, R., Steinfath, M., Balzereit, D., Eppens, B., Saran, N.G., Pletcher, M.T., South, S.T., Stetten, G., et al. (2004). Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res. 14, 1258-1267. (Pubitemid 39029222)
160. Karrer, J.H., Karrer, R., Bloom, D., Chaney, L., and Davis, R. (1998). Event-related brain potentials during an extended visual recognition memory task depict delayed development of cerebral inhibitory processes among 6-month-old infants with Down syndrome. Int. J. Psychophysiol. 29, 167-200. (Pubitemid 28306604)
161. Katoh, Y. and Katoh, M. (2009). Hedgehog target genes: Mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 9, 873-886.
162. Kim, S.H., Yoo, B.C., Broers, J.L., Cairns, N., and Lubec, G. (2000). Neuroendocrine-specific protein C, a marker of neuronal differentiation, is reduced in brain of patients with Down syndrome and Alzheimer's disease. Biochem. Biophys. Res. Commun. 276, 329-334.
163. Kim, Y., Park, J., Song, W.J., and Chang, S. (2010). Overexpression of Dyrk1A Causes the Defects in Synaptic Vesicle Endocytosis. Neurosignals 18, 164-172.
164. Kishnani, P.S., Heller, J.H., Spiridigliozzi, G.A., Lott, I., Escobar, L., Richardson, S., Zhang, R., and McRae, T. (2010). Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am. J. Med. Genet. A 152A, 3028-3035.
165. Klein, S.L., Kriegsfeld, L.J., Hairston, J.E., Rau, V., Nelson, R.J., and Yarowsky, P.J. (1996). Characterization of sensorimotor performance, reproductive and aggressive behaviors in segmental trisomic 16 (Ts65Dn) mice. Physiol. Behav. 60, 1159-1164. (Pubitemid 26336736)
166. Kleschevnikov, A.M., Belichenko, P.V., Villar, A.J., Epstein, C.J., Malenka, R.C., and Mobley, W.C. (2004). Hippocampal longterm potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24, 8153-8160. (Pubitemid 39280835)
167. Koo, B.K., Blaser, S., Harwood-Nash, D., Becker, L.E., and Murphy, E.G. (1992). Magnetic resonance imaging evaluation of delayed myelination in Down syndrome: A case report and review of the literature. J. Child Neurol. 7, 417-421.
168. Korenberg, J.R., Chen, X.N., Schipper, R., Sun, Z., Gonsky, R., Gerwehr, S., Carpenter, N., Daumer, C., Dignan, P., Disteche, C., et al. (1994). Down syndrome phenotypes: The consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. USA 91, 4997-5001. (Pubitemid 24177778)
169. Kurt, M.A., Davies, D.C., Kidd, M., Dierssen, M., and Florez, J. (2000). Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Res. 858, 191-197. (Pubitemid 30105799)
170. Kurt, M.A., Kafa, M.I., Dierssen, M., and Davies, D.C. (2004). Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 1022, 101-109. (Pubitemid 39194990)
171. Lai, K., Kaspar, B.K., Gage, F.H., and Schaffer, D.V. (2003). Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat. Neurosci. 6, 21-27. (Pubitemid 36026328)
172. Li, Y., Wang, J., Sheng, J.G., Liu, L., Barger, S.W., Jones, R.A., Van Eldik, L.J., Mrak, R.E., and Griffin, W.S. (1998). S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J. Neurochem. 71, 1421-1428. (Pubitemid 28443012)
173. Li, Z., Yu, T., Morishima, M., Pao, A., LaDuca, J., Conroy, J., Nowak, N., Matsui, S., Shiraishi, I., and Yu, Y.E. (2007). Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum. Mol. Genet. 16, 1359-1366. (Pubitemid 47055132)
174. Lieberman, D.N. and Mody, I. (1994). Regulation of NMDA channel function by endogenous Ca(2+ )-dependent phosphatase. Nature 369, 235-239. (Pubitemid 24154801)
175. Lockrow, J., Prakasam, A., Huang, P., Bimonte-Nelson, H., Sambamurti, K., and Granholm, A.C. (2009). Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp. Neurol. 216, 278-289.
176. Lockrow, J., Boger, H., Bimonte-Nelson, H., and Granholm, A.C. (2011a). Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 221, 610-622.
177. Lockrow, J., Boger, H., Gerhardt, G., Bachman, D., and Granholm, A.C. (2011b). A Noradrenergic Lesion Exacerbates Neurodegeneration in a Down Syndrome Mouse Model. J. Alzheimers Dis. 23, 471-489.
178. Lorenzi, H.A. and Reeves, R.H. (2006). Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res. 1104, 153-159. (Pubitemid 44148518)
179. Louvi, A. and Artavanis-Tsakonas, S. (2006). Notch signalling in vertebrate neural development. Nat. Rev. Neurosci. 7, 93-102. (Pubitemid 43151596)
180. Lubec, B., Weitzdoerfer, R., and Fountoulakis, M. (2001). Manifold reduction of moesin in fetal Down syndrome brain. Biochem. Biophys. Res. Commun. 286, 1191-1194. (Pubitemid 32924896)
181. Luscher, C., Jan, L.Y., Stoffel, M., Malenka, R.C., and Nicoll, R.A. (1997). G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 19, 687-695. (Pubitemid 27430754)
182. Lydic, J. (1979). Assessment of the quality of sitting and gait patterns in children with Down's syndrome. Phys. Ther. 12, 1489-1494. (Pubitemid 10169537)
183. Lyle, R., Gehrig, C., Neergaard-Henrichsen, C., Deutsch, S., and Antonarakis, S.E. (2004). Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Res. 14, 1268-1274. (Pubitemid 39029223)
184. Lyle, R., Bena, F., Gagos, S., Gehrig, C., Lopez, G., Schinzel, A., Lespinasse, J., Bottani, A., Dahoun, S., Taine, L., et al. (2009). Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur. J. Hum. Genet. 17, 454-466.
185. Malberg, J.E. and Blendy, J.A. (2005). Antidepressant action: To the nucleus and beyond. Trends Pharmacol. Sci. 26, 631-638. (Pubitemid 41636308)
186. Malberg, J.E., Eisch, A.J., Nestler, E.J., and Duman, R.S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20, 9104-9110. (Pubitemid 32042912)
187. Mann, D.M., Yates, P.O., Marcyniuk, B., and Ravindra, C.R. (1985). Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J. Ment. Defic. Res. 29 (Pt 2), 125-135. (Pubitemid 15029018)
188. Mansuy, I.M. (2003). Calcineurin in memory and bidirectional plasticity. Biochem. Biophys. Res. Commun. 311, 1195-1208. (Pubitemid 37393442)
189. Mao, R., Zielke, C.L., Zielke, H.R., and Pevsner, J. (2003). Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics 81, 457-467. (Pubitemid 36437522)
190. Marin-Padilla, M. (1976). Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. J. Comp. Neurol. 167, 63-81.
191. Martinez-Cue, C., Baamonde, C., Lumbreras, M., Paz, J., Davisson, M.T., Schmidt, C., Dierssen, M., and Florez, J. (2002). Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 134, 185-200. (Pubitemid 34912698)
192. Martinez-Cue, C., Rueda, N., Garcia, E., Davisson, M.T., Schmidt, C., and Florez, J. (2005). Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome. Behav. Brain Res. 163, 174-185. (Pubitemid 41138051)
193. Meakin, S.O. and Shooter, E.M. (1992). The nerve growth factor family of receptors. Trends Neurosci. 15, 323-331.
194. Meakin, S.O., Suter, U., Drinkwater, C.C., Welcher, A.A., and Shooter, E.M. (1992). The rat trk protooncogene product exhibits properties characteristic of the slow nerve growth factor receptor. Proc. Natl. Acad. Sci. USA 89, 2374-2378.
195. Megias, M., Verduga, R., Dierssen, M., Florez, J., Insausti, R., and Crespo, D. (1997). Cholinergic, serotonergic and catecholaminergic neurons are not affected in Ts65Dn mice. Neuroreport 8, 3475-3478. (Pubitemid 27497467)
196. Mito, T. and Becker, L.E. (1993). Developmental changes of S-100 protein and glial fibrillary acidic protein in the brain in Down syndrome. Exp. Neurol. 120, 170-176. (Pubitemid 23165012)
197. Mohan, M., Bennett, C., and Carpenter, P.K. (2009a). Galantamine for dementia in people with Down syndrome. Cochrane Database Syst. Rev. CD007656.
198. Mohan, M., Bennett, C., and Carpenter, P.K. (2009b). Memantine for dementia in people with Down syndrome. Cochrane Database Syst. Rev. CD007657.
199. Mohan, M., Bennett, C., and Carpenter, P.K. (2009c). Rivastigmine for dementia in people with Down syndrome. Cochrane Database Syst. Rev. CD007658.
200. Mohan, M., Carpenter, P.K., and Bennett, C. (2009d). Donepezil for dementia in people with Down syndrome. Cochrane Database Syst. Rev. CD007178.
201. Moldrich, R.X., Dauphinot, L., Laffaire, J., Vitalis, T., Herault, Y., Beart, P.M., Rossier, J., Vivien, D., Gehrig, C., Antonarakis, S.E., et al. (2009). Proliferation deficits and gene expression dysregulation in Down's syndrome (Ts1Cje) neural progenitor cells cultured from neurospheres. J. Neurosci. Res. 87, 3143-3152.
202. Moran, T.H., Capone, G.T., Knipp, S., Davisson, M.T., Reeves, R.H., and Gearhart, J.D. (2002). The effects of piracetam on cognitive performance in a mouse model of Down's syndrome. Physiol. Behav. 77, 403-409. (Pubitemid 35373895)
203. Morice, E., Andreae, L.C., Cooke, S.F., Vanes, L., Fisher, E.M., Tybulewicz, V.L., and Bliss, T.V. (2008). Preservation of longterm memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome. Learn. Mem. 15, 492-500. (Pubitemid 352008671)
204. Morrison, S.J., Perez, S.E., Qiao, Z., Verdi, J.M., Hicks, C., Weinmaster, G., and Anderson, D.J. (2000). Transient Notch activation initiates an irreversible switch from neurogenesis to gliogenesis by neural crest stem cells. Cell 101, 499-510.
205. Mucke, L. (2009). Neuroscience: Alzheimer's disease. Nature 461, 895-897.
206. Muller, T., Meyer, H.E., Egensperger, R., and Marcus, K. (2008). The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog. Neurobiol. 85, 393-406.
207. Murchison, C.F., Zhang, X.Y., Zhang, W.P., Ouyang, M., Lee, A., and Thomas, S.A. (2004). A distinct role for norepinephrine in memory retrieval. Cell 117, 131-143. (Pubitemid 38469904)
208. Nadel, L. (2003). Down's syndrome: A genetic disorder in biobehavioral perspective. Genes Brain Behav. 2, 156-166. (Pubitemid 36898802)
209. Nagy, Z.S. and Esiri, M.M. (1997). Apoptosis-related protein expression in the hippocampus in Alzheimer's disease. Neurobiol. Aging 18, 565-571. (Pubitemid 28046409)
210. Netzer, W.J., Powell, C., Nong, Y., Blundell, J., Wong, L., Duff, K., Flajolet, M., and Greengard, P. (2010). Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One 5, e10943.
211. O'Doherty, A., Ruf, S., Mulligan, C., Hildreth, V., Errington, M.L., Cooke, S., Sesay, A., Modino, S., Vanes, L., Hernandez, D., et al. (2005). An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309, 2033-2037. (Pubitemid 41362316)
212. Ohara, S., Tsukada, M., and Ikeda, S. (1999). On the occurrence of neuronal sprouting in the frontal cortex of a patient with Down's syndrome. Acta Neuropathol. 97, 85-90. (Pubitemid 29132650)
213. Olson, L.E., Richtsmeier, J.T., Leszl, J., and Reeves, R.H. (2004a). A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 306, 687-690. (Pubitemid 39440917)
214. Olson, L.E., Roper, R.J., Baxter, L.L., Carlson, E.J., Epstein, C.J., and Reeves, R.H. (2004b). Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev. Dyn. 230, 581-589. (Pubitemid 38802484)
215. Olson, L.E., Roper, R.J., Sengstaken, C.L., Peterson, E.A., Aquino, V., Galdzicki, Z., Siarey, R., Pletnikov, M., Moran, T.H., and Reeves, R.H. (2007). Trisomy for the Down syndrome'critical region'is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol. Genet. 16, 774-782. (Pubitemid 47061624)
216. Palma, V., Lim, D.A., Dahmane, N., Sanchez, P., Brionne, T.C., Herzberg, C.D., Gitton, Y., Carleton, A., Alvarez-Buylla, A., and Ruiz i Altaba, A. (2005). Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. Development 132, 335-344. (Pubitemid 40268283)
217. Park, J., Yang, E.J., Yoon, J.H., and Chung, K.C. (2007). Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome. Mol. Cell Neurosci. 36, 270-279. (Pubitemid 47418617)
218. Park, J., Oh, Y., Yoo, L., Jung, M.S., Song, W.J., Lee, S.H., Seo, H., and Chung, K.C. (2010). Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. J. Biol. Chem. 285, 31895-31906.
219. Pastor, M.C., Sierra, C., Dolade, M., Navarro, E., Brandi, N., Cabre, E., Mira, A., and Seres, A. (1998). Antioxidant enzymes and fatty acid status in erythrocytes of Down's syndrome patients. Clin. Chem. 44, 924-929. (Pubitemid 28213130)
220. Pelsman, A., Hoyo-Vadillo, C., Gudasheva, T.A., Seredenin, S.B., Ostrovskaya, R.U., and Busciglio, J. (2003). GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int. J. Dev. Neurosci. 21, 117-124. (Pubitemid 36444536)
221. Percy, M.E., Dalton, A.J., Markovic, V.D., McLachlan, D.R., Hummel, J.T., Rusk, A.C., and Andrews, D.F. (1990). Red cell superoxide dismutase, glutathione peroxidase and catalase in Down syndrome patients with and without manifestations of Alzheimer disease. Am. J. Med. Genet. 35, 459-467. (Pubitemid 20109002)
222. Pereira, P.L., Magnol, L., Sahun, I., Brault, V., Duchon, A., Prandini, P., Gruart, A., Bizot, J.C., Chadefaux-Vekemans, B., Deutsch, S., et al. (2009). A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Hum. Mol. Genet. 18, 4756-4769.
223. Perez-Cremades, D., Hernandez, S., Blasco-Ibanez, J.M., Crespo, C., Nacher, J., and Varea, E. (2010). Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J. Neural Transm. 117, 445-455.
224. Perez-Otano, I. and Ehlers, M.D. (2004). Learning from NMDA receptor trafficking: Clues to the development and maturation of glutamatergic synapses. Neurosignals 13, 175-189. (Pubitemid 38698090)
225. Phillips, R.G. and LeDoux, J.E. (1992). Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. 106, 274-285.
226. Pinter, J.D., Eliez, S., Schmitt, J.E., Capone, G.T., and Reiss, A.L. (2001). Neuroanatomy of Down's syndrome: A high-resolution MRI study. Am. J. Psychiatry 158, 1659-1665. (Pubitemid 32923659)
227. Pollak, D., Cairns, N., and Lubec, G. (2003). Cytoskeleton derangement in brain of patients with Down syndrome, Alzheimer's disease and Pick's disease. J. Neural. Transm. Suppl. 67, 149-158. (Pubitemid 38339930)
228. Pollonini, G., Gao, V., Rabe, A., Palminiello, S., Albertini, G., and Alberini, C.M. (2008). Abnormal expression of synaptic proteins and neurotrophin-3 in the Down syndrome mouse model Ts65Dn. Neuroscience 156, 99-106.
229. Popov, V.I., Kleschevnikov, A.M., Klimenko, O.A., Stewart, M.G., and Belichenko, P.V. (2011). Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of down syndrome. J. Comp. Neurol. 519, 1338-1354.
230. Porta, S., Serra, S.A., Huch, M., Valverde, M.A., Llorens, F., Estivill, X., Arbones, M.L., and Marti, E. (2007). RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: A potential pathogenic process in neurodegeneration. Hum. Mol. Genet. 16, 1039-1050. (Pubitemid 47062725)
231. Prinz, M., Prinz, B., and Schulz, E. (1997). The growth of nonpyramidal neurons in the primary motor cortex of man: A Golgi study. Histol. Histopathol. 12, 895-900. (Pubitemid 27410444)
232. Purpura, D.P. (1979). Pathobiology of cortical neurons in metabolic and unclassified amentias. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 57, 43-68.
233. Rachidi, M. and Lopes, C. (2008). Mental retardation and associated neurological dysfunctions in Down syndrome: A consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur. J. Paediatr. Neurol. 12, 168-182. (Pubitemid 351545848)
234. Raz, N., Torres, I.J., Briggs, S.D., Spencer, W.D., Thornton, A.E., Loken, W.J., Gunning, F.M., McQuain, J.D., Driesen, N.R., and Acker, J.D. (1995). Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: Evidence from MRI morphometry. Neurology 45, 356-366.
235. Reeves, R.H., Irving, N.G., Moran, T.H., Wohn, A., Kitt, C., Sisodia, S.S., Schmidt, C., Bronson, R.T., and Davisson, M.T. (1995). A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 11, 177-184.
236. Represa, A. and Ben-Ari, Y. (2005). Trophic actions of GABA on neuronal development. Trends Neurosci. 28, 278-283. (Pubitemid 40775771)
237. Richtsmeier, J.T., Baxter, L.L., and Reeves, R.H. (2000). Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice. Dev. Dyn. 217, 137-145. (Pubitemid 30080493)
238. Risser, D., Lubec, G., Cairns, N., and Herrera-Marschitz, M. (1997). Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci. 60, 1231-1237. (Pubitemid 27191762)
239. Robertson, R.T., Baratta, J., Yu, J., and Guthrie, K.M. (2006). A role for neurotrophin-3 in targeting developing cholinergic axon projections to cerebral cortex. Neuroscience 143, 523-539. (Pubitemid 44724938)
240. Roizen, N.J. and Patterson, D. (2003). Down's syndrome. Lancet 361, 1281-1289. (Pubitemid 36428586)
241. Roper, R.J., Baxter, L.L., Saran, N.G., Klinedinst, D.K., Beachy, P.A., and Reeves, R.H. (2006). Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice. Proc. Natl. Acad. Sci. USA 103, 1452-1456. (Pubitemid 43191186)
242. Ross, M.H., Galaburda, A.M., and Kemper, T.L. (1984). Down's syndrome: Is there a decreased population of neurons? Neurology 34, 909-916. (Pubitemid 14076456)
243. Rueda, N., Florez, J., and Martinez-Cue, C. (2008a). Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 433, 22-27.
244. Rueda, N., Florez, J., and Martinez-Cue, C. (2008b). Effects of chronic administration of SGS-111 during adulthood and during the pre-and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome. Behav. Brain Res. 188, 355-367.
245. Rueda, N., Llorens-Martin, M., Florez, J., Valdizan, E., Banerjee, P., Trejo, J.L., and Martinez-Cue, C. (2010). Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J. Alzheimers Dis. 21, 277-290.
246. Ryoo, S.R., Cho, H.J., Lee, H.W., Jeong, H.K., Radnaabazar, C., Kim, Y.S., Kim, M.J., Son, M.Y., Seo, H., Chung, S.H., et al. (2008). Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: Evidence for a functional link between Down syndrome and Alzheimer's disease. J. Neurochem. 104, 1333-1344. (Pubitemid 351293338)
247. Sago, H., Carlson, E.J., Smith, D.J., Kilbridge, J., Rubin, E.M., Mobley, W.C., Epstein, C.J., and Huang, T.T. (1998). Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl. Acad. Sci. USA 95, 6256-6261. (Pubitemid 28248999)
248. Sago, H., Carlson, E.J., Smith, D.J., Rubin, E.M., Crnic, L.S., Huang, T.T., and Epstein, C.J. (2000). Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome. Pediatr. Res. 48, 606-613.
249. Sahir, N., Brenneman, D.E., and Hill, J.M. (2006). Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation. J. Mol. Neurosci. 30, 329-340. (Pubitemid 46568351)
250. Sairanen, M., Lucas, G., Ernfors, P., Castren, M., and Castren, E. (2005). Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci. 25, 1089-1094. (Pubitemid 40268949)
251. Salehi, A., Delcroix, J.D., Belichenko, P.V., Zhan, K., Wu, C., Valletta, J.S., Takimoto-Kimura, R., Kleschevnikov, A.M., Sambamurti, K., Chung, P.P., et al. (2006). Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29-42. (Pubitemid 43963336)
252. Salehi, A., Faizi, M., Colas, D., Valletta, J., Laguna, J., Takimoto- Kimura, R., Kleschevnikov, A., Wagner, S.L., Aisen, P., Shamloo, M., et al. (2009). Restoration of norepinephrinemodulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 1, 7-17.
253. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809. (Pubitemid 36962615)
254. Sawa, A., Oyama, F., Cairns, N.J., Amano, N., and Matsushita, M. (1997). Aberrant expression of bcl-2 gene family in Down's syndrome brains. Brain Res. Mol. Brain Res. 48, 53-59. (Pubitemid 27298128)
255. Schapiro, M.B., Creasey, H., Schwartz, M., Haxby, J.V., White, B., Moore, A., and Rapoport, S.I. (1987). Quantitative CT analysis of brain morphometry in adult Down's syndrome at different ages. Neurology 37, 1424-1427.
256. Schmid, R.G., Tirsch, W.S., Rappelsberger, P., Weinmann, H.M., and Poppl, S.J. (1992). Comparative coherence studies in healthy volunteers and Down's syndrome patients from childhood to adult age. Electroencephalogr. Clin. Neurophysiol. 83, 112-123.
257. Schmidt, A.M., Yan, S.D., Yan, S.F., and Stern, D.M. (2001). The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108, 949-955. (Pubitemid 32946067)
258. Schmidt-Sidor, B., Wisniewski, K.E., Shepard, T.H., and Sersen, E.A. (1990). Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. Clin. Neuropathol. 9, 181-190. (Pubitemid 20287898)
259. Schuchmann, S., Muller, W., and Heinemann, U. (1998). Altered Ca2+ signaling and mitochondrial deficiencies in hippocampal neurons of trisomy 16 mice: A model of Down's syndrome. J. Neurosci. 18, 7216-7231. (Pubitemid 28425808)
260. Schulz, E. and Scholz, B. (1992). Neurohistological findings in the parietal cortex of children with chromosome aberrations. J. Hirnforsch. 33, 37-62.
261. Schulz, J.B., Weller, M., and Moskowitz, M.A. (1999). Caspases as treatment targets in stroke and neurodegenerative diseases. Ann. Neurol. 45, 421-429. (Pubitemid 29165807)
262. Schwartz, N., Schohl, A., and Ruthazer, E.S. (2009). Neural activity regulates synaptic properties and dendritic structure in vivo through calcineurin/NFAT signaling. Neuron 62, 655-669.
263. Seidl, R., Fang-Kircher, S., Bidmon, B., Cairns, N., and Lubec, G. (1999). Apoptosis-associated proteins p53 and APO-1/ Fas (CD95) in brains of adult patients with Down syndrome. Neurosci. Lett. 260, 9-12. (Pubitemid 29066889)
264. Sementchenko, V.I. and Watson, D.K. (2000). Ets target genes: Past, present and future. Oncogene 19, 6533-6548. (Pubitemid 32108443)
265. Seo, H. and Isacson, O. (2005). Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp. Neurol. 193, 469-480. (Pubitemid 40626769)
266. Shah, S.N. (1979). Fatty acid composition of lipids of human brain myelin and synaptosomes: Changes in phenylketonuria and Down's syndrome. Int. J. Biochem. 10, 477-482. (Pubitemid 9203531)
267. Shankaran, M., King, C., Lee, J., Busch, R., Wolff, M., and Hellerstein, M.K. (2006). Discovery of novel hippocampal neurogenic agents by using an in vivo stable isotope labeling technique. J. Pharmacol. Exp. Ther. 319, 1172-1181.
268. Shapiro, B.L. (1997). Whither Down syndrome critical regions? Hum. Genet. 99, 421-423. (Pubitemid 27095809)
269. Shapiro, L.A. and Whitaker-Azmitia, P.M. (2004). Expression levels of cytoskeletal proteins indicate pathological aging of S100B transgenic mice: An immunohistochemical study of MAP-2, drebrin and GAP-43. Brain Res. 1019, 39-46. (Pubitemid 39078608)
270. Shichiri, M., Yoshida, Y., Ishida, N., Hagihara, Y., Iwahashi, H., Tamai, H., and Niki, E. (2011). alpha-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free. Radic. Biol. Med. 15, 1801-1811.
271. Shim, K.S. and Lubec, G. (2002). Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci. Lett. 324, 209-212. (Pubitemid 34493871)
272. Shin, J.H., Gulesserian, T., Weitzdoerfer, R., Fountoulakis, M., and Lubec, G. (2004). Derangement of hypothetical proteins in fetal Down's syndrome brain. Neurochem. Res. 29, 1307-1316. (Pubitemid 39023503)
273. Shin, M., Besser, L.M., Kucik, J.E., Lu, C., Siffel, C., and Correa, A. (2009). Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. Pediatrics 124, 1565-1571.
274. Shukkur, E.A., Shimohata, A., Akagi, T., Yu, W., Yamaguchi, M., Murayama, M., Chui, D., Takeuchi, T., Amano, K., Subramhanya, K.H., et al. (2006). Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum. Mol. Genet. 15, 2752-2762. (Pubitemid 44400402)
275. Siarey, R.J., Villar, A.J., Epstein, C.J., and Galdzicki, Z. (2005). Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology 49, 122-128. (Pubitemid 40910022)
276. Siddiqui, A., Lacroix, T., Stasko, M.R., Scott-McKean, J.J., Costa, A.C., and Gardiner, K.J. (2008). Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. Genes Brain. Behav. 7, 810-820.
277. Sidman, R.L. and Rakic, P. (1973). Neuronal migration, with special reference to developing human brain: A review. Brain Res. 62, 1-35.
278. Smith, D.J., Zhu, Y., Zhang, J., Cheng, J.F., and Rubin, E.M. (1995). Construction of a panel of transgenic mice containing a contiguous 2-Mb set of YAC/P1 clones from human chromosome 21q22.2. Genomics 27, 425-434.
279. Smith, D.J., Stevens, M.E., Sudanagunta, S.P., Bronson, R.T., Makhinson, M., Watabe, A.M., O'Dell, T.J., Fung, J., Weier, H.U., Cheng, J.F., et al. (1997). Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat. Genet. 16, 28-36. (Pubitemid 27198153)
280. Sofroniew, M.V., Howe, C.L., and Mobley, W.C. (2001). Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 24, 1217-1281. (Pubitemid 32695259)
281. Song, W.J., Sternberg, L.R., Kasten-Sportes, C., Keuren, M.L., Chung, S.H., Slack, A.C., Miller, D.E., Glover, T.W., Chiang, P.W., Lou, L., et al. (1996). Isolation of human and murine homologues of the Drosophila minibrain gene: Human homologue maps to 21q22.2 in the Down syndrome "critical region". Genomics 38, 331-339. (Pubitemid 27030122)
282. Stack, E.C., Smith, K.M., Ryu, H., Cormier, K., Chen, M., Hagerty, S.W., Del Signore, S.J., Cudkowicz, M.E., Friedlander, R.M., and Ferrante, R.J. (2006). Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 1762, 373-380. (Pubitemid 43172854)
283. Stadelmann, C., Deckwerth, T.L., Srinivasan, A., Bancher, C., Bruck, W., Jellinger, K., and Lassmann, H. (1999). Activation of caspase- 3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am. J. Pathol. 155, 1459-1466.
284. Stasko, M.R. and Costa, A.C. (2004). Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome. Behav. Brain Res. 154, 1-17. (Pubitemid 39070448)
285. Stewart, L.S. (2007). Chronobiometry of Behavioral Activity in the Ts65Dn Model of Down Syndrome. Behav. Genet. 37, 388-398. (Pubitemid 46425331)
286. Stoel Gammon, C. (2001). Down syndrome phonology: Developmental patterns and intervention strategies. Downs Syndr. Res. Pract. 7, 93-100.
287. Sudarov, A. and Joyner, A.L. (2007). Cerebellum morphogenesis: The foliation pattern is orchestrated by multi-cellular anchoring centers. Neural. Dev. 2, 26.
288. Suetsugu, M. and Mehraein, P. (1980). Spine distribution along the apical dendrites of the pyramidal neurons in Down's syndrome. A quantitative Golgi study. Acta Neuropathol. 50, 207-210. (Pubitemid 10030034)
289. Sumarsono, S.H., Wilson, T.J., Tymms, M.J., Venter, D.J., Corrick, C.M., Kola, R., Lahoud, M.H., Papas, T.S., Seth, A., and Kola, I. (1996). Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nature 379, 534-537. (Pubitemid 26049578)
290. Sylvester, P.E. (1986). The anterior commissure in Down's syndrome. J. Ment. Defic. Res. 30 (Pt 1), 19-26. (Pubitemid 16142019)
291. Takashima, S., Becker, L.E., Armstrong, D.L., and Chan, F. (1981). Abnormal neuronal development in the visual cortex of the human fetus and infant with down's syndrome. A quantitative and qualitative Golgi study. Brain Res. 225, 1-21. (Pubitemid 11026571)
292. Takashima, S., Ieshima, A., Nakamura, H., and Becker, L.E. (1989). Dendrites, dementia and the Down syndrome. Brain Dev. 11, 131-133. (Pubitemid 19106477)
293. Takashima, S., Iida, K., Mito, T., and Arima, M. (1994). Dendritic and histochemical development and ageing in patients with Down's syndrome. J. Intellect. Disabil. Res. 38 (Pt 3), 265-273. (Pubitemid 24168352)
294. Tamagno, E., Robino, G., Obbili, A., Bardini, P., Aragno, M., Parola, M. and Danni, O. (2003). H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp. Neurol. 180, 144-155. (Pubitemid 36398169)
295. Teipel, S.J., Schapiro, M.B., Alexander, G.E., Krasuski, J.S., Horwitz, B., Hoehne, C., Moller, H.J., Rapoport, S.I., and Hampel, H. (2003). Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. Am. J. Psychiatry 160, 1870-1878. (Pubitemid 41103323)
296. Thomas, S.J. and Grossberg, G.T. (2009). Memantine: A review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin. Interv. Aging 4, 367-377.
297. Toiber, D., Azkona, G., Ben-Ari, S., Toran, N., Soreq, H., and Dierssen, M. (2010). Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. Neurobiol. Dis. 40, 348-359.
298. Toso, L., Cameroni, I., Roberson, R., Abebe, D., Bissell, S., and Spong, C.Y. (2008). Prevention of developmental delays in a Down syndrome mouse model. Obstet. Gynecol. 112, 1242-1251.
299. Trazzi, S., Mitrugno, V.M., Valli, E., Fuchs, C., Rizzi, S., Guidi, S., Perini, G., Bartesaghi, R., and Ciani, E. (2011). APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Hum. Mol. Genet. 20, 1560-1573.
300. Vacik, T., Ort, M., Gregorova, S., Strnad, P., Blatny, R., Conte, N., Bradley, A., Bures, J., and Forejt, J. (2005). Segmental trisomy of chromosome 17: A mouse model of human aneuploidy syndromes. Proc. Natl. Acad. Sci. USA 102, 4500-4505. (Pubitemid 40397141)
301. Vicari, S. (2006). Motor development and neuropsychological patterns in persons with Down syndrome. Behav. Genet. 36, 355-364. (Pubitemid 43876775)
302. Vicari, S., Bellucci, S., and Carlesimo, G.A. (2000). Implicit and explicit memory: A functional dissociation in persons with Down syndrome. Neuropsychologia 38, 240-251.
303. Villar, A.J., Belichenko, P.V., Gillespie, A.M., Kozy, H.M., Mobley, W.C., and Epstein, C.J. (2005). Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12. Mamm. Genome 16, 79-90. (Pubitemid 40895684)
304. Vink, J., Incerti, M., Toso, L., Roberson, R., Abebe, D., and Spong, C.Y. (2009). Prenatal NAP+ SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors. Am. J. Obstet. Gynecol. 200, 524 e521-524.
305. Voronov, S.V., Frere, S.G., Giovedi, S., Pollina, E.A., Borel, C., Zhang, H., Schmidt, C., Akeson, E.C., Wenk, M.R., Cimasoni, L., et al. (2008). Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome. Proc. Natl. Acad. Sci. USA 105, 9415-9420.
306. Vuksic, M., Petanjek, Z., Rasin, M.R., and Kostovic, I. (2002). Perinatal growth of prefrontal layer III pyramids in Down syndrome. Pediatr. Neurol. 27, 36-38. (Pubitemid 34823589)
307. Wang, P.P., Doherty, S., Hesselink, J.R., and Bellugi, U. (1992). Callosal morphology concurs with neurobehavioral and neuropathological findings in two neurodevelopmental disorders. Arch. Neurol. 49, 407-411.
308. Wang, J.W., David, D.J., Monckton, J.E., Battaglia, F., and Hen, R. (2008). Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J. Neurosci. 28, 1374-1384. (Pubitemid 351231535)
309. Wegiel, J., Dowjat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur Kolecka, B., Silverman, W.P., Reisberg, B., Deleon, M., et al. (2008). The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol. 116, 391-407.
310. Weis, S., Weber, G., Neuhold, A., and Rett, A. (1991). Down syndrome: MR quantification of brain structures and comparison with normal control subjects. AJNR Am. J. Neuroradiol. 12, 1207-1211.
311. Weitzdoerfer, R., Dierssen, M., Fountoulakis, M., and Lubec, G. (2001). Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. J. Neural. Transm. Suppl. 61, 59-70. (Pubitemid 38085072)
312. Weitzdoerfer, R., Fountoulakis, M., and Lubec, G. (2002). Reduction of actin-related protein complex 2/3 in fetal Down syndrome brain. Biochem. Biophys. Res. Commun. 293, 836-841. (Pubitemid 34687264)
313. Wenk, G.L., McGann, K., Mencarelli, A., Hauss-Wegrzyniak, B., Del Soldato, P., and Fiorucci, S. (2000). Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur. J. Pharmacol. 402, 77-85. (Pubitemid 30625313)
314. Wexler, E.M., Geschwind, D.H., and Palmer, T.D. (2008). Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol. Psychiatry 13, 285-292. (Pubitemid 351272655)
315. Whitaker-Azmitia, P.M. (2001). Serotonin and brain development: Role in human developmental diseases. Brain Res. Bull. 56, 479-485. (Pubitemid 34031783)
316. White, N.S., Alkire, M.T., and Haier, R.J. (2003). A voxel-based morphometric study of nondemented adults with Down Syndrome. Neuroimage 20, 393-403. (Pubitemid 37188527)
317. Whittle, N., Sartori, S.B., Dierssen, M., Lubec, G., and Singewald, N. (2007). Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics 120, e1465-1471. (Pubitemid 350223666)
318. Winblad, B. (2005). Piracetam: A review of pharmacological properties and clinical uses. CNS Drug Rev. 11, 169-182. (Pubitemid 41278980)
319. Winter, T.C., Ostrovsky, A.A., Komarniski, C.A., and Uhrich, S.B. (2000). Cerebellar and frontal lobe hypoplasia in fetuses with trisomy 21: Usefulness as combined US markers. Radiology 214, 533-538. (Pubitemid 30077715)
320. Wisniewski, K., Howe, J., Williams, D.G., and Wisniewski, H.M. (1978). Precocious aging and dementia in patients with Down's syndrome. Biol. Psychiatry 13, 619-627. (Pubitemid 9041470)
321. Wisniewski, K.E. (1990). Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am. J. Med. Genet. Suppl. 7, 274-281.
322. Wisniewski, K.E. and Schmidt-Sidor, B. (1989). Postnatal delay of myelin formation in brains from Down syndrome infants and children. Clin. Neuropathol. 8, 55-62. (Pubitemid 19169365)
323. Wisniewski, K.E., Dalton, A.J., McLachlan, C., Wen, G.Y., and Wisniewski, H.M. (1985a). Alzheimer's disease in Down's syndrome: Clinicopathologic studies. Neurology 35, 957-961. (Pubitemid 15026265)
324. Wisniewski, K.E., Wisniewski, H.M., and Wen, G.Y. (1985b). Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17, 278-282. (Pubitemid 15136603)
325. Wolvetang, E.J., Wilson, T.J., Sanij, E., Busciglio, J., Hatzistavrou, T., Seth, A., Hertzog, P.J., and Kola, I. (2003). ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. Hum. Mol. Genet. 12, 247-255. (Pubitemid 36204422)
326. Xie, W., Ramakrishna, N., Wieraszko, A., and Hwang, Y.W. (2008). Promotion of neuronal plasticity by (-)-epigallocatechin-3-gallate. Neurochem. Res. 33, 776-783. (Pubitemid 351423141)
327. Yabut, O., Domogauer, J., and D'Arcangelo, G. (2010). Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. J. Neurosci. 30, 4004-4014.
328. Yang, E.J., Ahn, Y.S., and Chung, K.C. (2001). Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. J. Biol. Chem. 276, 39819-39824.
329. Yu, T., Li, Z., Jia, Z., Clapcote, S.J., Liu, C., Li, S., Asrar, S., Pao, A., Chen, R., Fan, N., et al. (2010). A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum. Mol. Genet. 19, 2780-2791.
330. Zang, D.W., Yang, Q., Wang, H.X., Egan, G., Lopes, E.C., and Cheema, S.S. (2004). Magnetic resonance imaging reveals neuronal degeneration in the brainstem of the superoxide dismutase 1 transgenic mouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 20, 1745-1751. (Pubitemid 39471567)
331. Zeng, H., Chattarji, S., Barbarosie, M., Rondi-Reig, L., Philpot, B.D., Miyakawa, T., Bear, M.F., and Tonegawa, S. (2001). Forebrainspecific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 107, 617-629. (Pubitemid 34014863)